- Home
- RCMT vs IPHA Comparison
RCMT vs IPHA Comparison
Compare RCMT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCMT
- IPHA
- Stock Information
- Founded
- RCMT 1971
- IPHA 1999
- Country
- RCMT United States
- IPHA France
- Employees
- RCMT N/A
- IPHA N/A
- Industry
- RCMT Professional Services
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- RCMT Consumer Discretionary
- IPHA Health Care
- Exchange
- RCMT Nasdaq
- IPHA Nasdaq
- Market Cap
- RCMT 172.2M
- IPHA 160.1M
- IPO Year
- RCMT N/A
- IPHA 2019
- Fundamental
- Price
- RCMT $24.60
- IPHA $1.74
- Analyst Decision
- RCMT Strong Buy
- IPHA Strong Buy
- Analyst Count
- RCMT 2
- IPHA 1
- Target Price
- RCMT $33.50
- IPHA $11.00
- AVG Volume (30 Days)
- RCMT 80.4K
- IPHA 11.2K
- Earning Date
- RCMT 08-06-2025
- IPHA 09-11-2025
- Dividend Yield
- RCMT N/A
- IPHA N/A
- EPS Growth
- RCMT N/A
- IPHA N/A
- EPS
- RCMT 1.74
- IPHA N/A
- Revenue
- RCMT $290,914,000.00
- IPHA $20,831,349.00
- Revenue This Year
- RCMT $16.29
- IPHA $209.83
- Revenue Next Year
- RCMT $6.16
- IPHA $83.15
- P/E Ratio
- RCMT $14.15
- IPHA N/A
- Revenue Growth
- RCMT 8.53
- IPHA N/A
- 52 Week Low
- RCMT $13.18
- IPHA $1.29
- 52 Week High
- RCMT $27.24
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- RCMT 55.47
- IPHA 42.70
- Support Level
- RCMT $22.48
- IPHA $1.71
- Resistance Level
- RCMT $27.24
- IPHA $1.90
- Average True Range (ATR)
- RCMT 1.22
- IPHA 0.08
- MACD
- RCMT 0.04
- IPHA 0.00
- Stochastic Oscillator
- RCMT 62.07
- IPHA 47.62
About RCMT RCM Technologies Inc.
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.